Q-omics provides the consensus-scored MTRNR2L5 profile across patient tissues and cancer cell-line models. MTRNR2L5 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, MTRNR2L5 is differentially expressed in 3, with the highest sampling consensus in READ. Additionally, MTRNR2L5 RNA expression shows 10,823 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight SCLC, READ, and ACC as cancer lineages where MTRNR2L5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTRNR2L5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTRNR2L5 survival associations across molecular data types. MTRNR2L5 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTRNR2L5 RNA expression–survival associations across cancer types. High MTRNR2L5 expression shows unfavorable associations in LUAD, but favorable associations in SCLC, MESO, KIRP, LGG and ESCA. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify SCLC as the clearest survival context for MTRNR2L5 RNA expression.
This table summarizes MTRNR2L5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in READ for RNA.
This table ranks reproducible tumor–normal expression differences for MTRNR2L5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTRNR2L5 shows lower tumor expression in READ and higher tumor expression in KICH and LIHC. The READ box plot shows higher MTRNR2L5 RNA expression in normal versus tumor tissue (log2 FC = −0.077, t-test p = .030).
This table shows molecular features associated with MTRNR2L5 in patient tissues and cancer cell lines. In patient samples, MTRNR2L5 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MTRNR2L5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
